Het Academisch Ziekenhuis van Luik is een ziekenhuis in de Belgische stad Luik. Het ziekenhuis is een academisch ziekenhuis verbonden aan de Université de Liège. Naast de hoofdcampus in Sart-Tilman waar 625 bedden zijn erkend heeft het ziekenhuis ook campussen of afdelingen in Chênée, Esneux en Fraiture-en-Condroz.

During the past decade, CHU de Liege conducted 278 clinical trials. In the 10-year time frame, 278 clinical trials started and 75 clinical trials were completed, i.e. on average, 27% percent of trials that started reached the finish line to date. In the past 5 years, 155 clinical trials started and 48 clinical trials were completed. i.e. 31% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Liege" #1 sponsor was "University of Liege" with 78 trials, followed by "Boehringer Ingelheim" with 21 trials sponsored, "The Lymphoma Academic Research Organisation" with 17 trials sponsored, "Pfizer" with 13 trials sponsored and "Bayer" with 13 trials sponsored. Other sponsors include 223 different institutions and companies that sponsored additional 152 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Liege" #1 collaborator was "Universitair Ziekenhuis Brussel" with 7 trials as a collaborator, "Centre Hospitalier Universitaire de Liege" with 6 trials as a collaborator, "University Hospital, Ghent" with 6 trials as a collaborator, "University of Liege" with 6 trials as a collaborator and "Belgium Health Care Knowledge Centre" with 4 trials as a collaborator. Other collaborators include 306 different institutions and companies that were collaborators in the rest 274 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Liege" are "Crohn Disease" (11 trials), "Critical Illness" (10 trials), "Multiple Myeloma" (9 trials), "Acute Myeloid Leukemia" (7 trials) and "Colitis, Ulcerative" (6 trials). Many other conditions were trialed in "CHU de Liege" in a lesser frequency.

Most popular intervention types in "CHU de Liege" are "Drug" (219 trials), "Other" (45 trials), "Device" (37 trials), "Biological" (34 trials) and "Procedure" (24 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (65 trials), "Rituximab" (7 trials), "Lenalidomide" (6 trials), "Carboplatin" (5 trials) and "Cisplatin" (5 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Liege" are 332 trials for "All" genders, 21 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are 133 active trials in "CHU de Liege". 4 are not yet recruiting, 88 are recruiting, 40 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 173 completed trials in CHU de Liege, 5 suspended trials, and 29 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Liege, 29 "Phase 1" clinical trials were conducted, 95 "Phase 2" clinical trials and 115 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 33 trials, and there were also 59 trials that are defined as “Not Applicable".

CHU de Liege has several departments that took part in Clinical trials: "Sart Tilman Hospital Department of Gastroenterology and Hepatology" - 3 trials, "Chu Sart Tilman; Medical Oncology" - 2 trials, "CHU de Liège - Service de Médecine Dentaire" - 2 trials